> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Deep Track Reports 6.01% Of GeneDx Class A Shares As A Passive Position
- URL: https://www.bullished.co/deep-track-reports-6-01-of-genedx-class-a-shares-as-a-passive-position-3e32ebfb/
- Published: 2026-11-17T21:41:02.000Z
- Updated: 2026-11-17T21:41:02.000Z
- Description: The adviser, its biotechnology fund and David Kroin reported the same 1.8 million shares with shared voting and disposal powers.
- Author: Matteo Parrino
- Tags: SEC Filings, WGS, Industry: Healthcare

Deep Track Capital, an investment adviser, reported a [6.01% stake](https://www.sec.gov/Archives/edgar/data/0001856083/000117266126005472/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [GeneDx](https://www.bullished.co/tag/wgs/), which provides genetic testing to diagnose genetic diseases, in a passive ownership disclosure filed Tuesday. The position covered 1.8 million Class A shares as of November 10.

## One Position, Shared Powers

Deep Track Biotechnology Master Fund, the fund named alongside the adviser, and David Kroin each reported the same 1.8 million shares. Kroin was identified as someone who may control Deep Track Capital; the reported holdings describe the same position, not separate blocks to add together.

All the reporting persons had shared authority to vote the shares and decide their disposal. Each reported zero shares over which they alone had voting or disposal authority.

The reporting persons [certified passive ownership](https://www.sec.gov/Archives/edgar/data/0001856083/000117266126005472/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co): they said the shares were neither bought nor held to change or influence control of GeneDx. The 6.01% figure applies specifically to its Class A common stock.

## Genetic Tests For Rare Disorders

GeneDx helps clinicians diagnose genetic diseases, particularly rare disorders affecting children. Its ExomeDx test examines protein-coding DNA, while GenomeDx examines the whole genome for changes that may explain disease.

Diagnostic test reports generated substantially all its revenue in the year ended December 31, 2025\. Insurers and other third-party payors, patients, business clients and healthcare partners pay for its services.

GeneDx's annual-report profile describes nearly 1,300 team members and an Infinity dataset built from over 2.5 million tests. That includes over 1 million exomes and genomes used to help interpret patients' results.

GeneDx's market capitalization was $1.5 billion as of Tuesday at 4:38 p.m. ET.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — Deep Track Capital, LP re: GeneDx Holdings Corp. (WGS)](https://www.sec.gov/Archives/edgar/data/0001856083/000117266126005472/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Next-Generation Sequencing Library Preparation Market Size, Share, and Forecast, 2026-2033 | Clinical Genomics Demand Drives 13.5% CAGR and USD 5.3 Billion Opportunity](https://uk.finance.yahoo.com/news/next-generation-sequencing-library-preparation-153700983.html?ref=bullished.co) — Yahoo Finance

### More on GeneDx

- [ARK Reports 6.42% GeneDx Stake Without Seeking To Influence Company Control](https://www.bullished.co/ark-reports-6-42-genedx-stake-without-seeking-to-influence-company-control-00f62c49/)
- [GeneDx Accepts Slower Test Growth To Get Paid — Some Orders Cannot Be Reimbursed](https://www.bullished.co/genedx-accepts-slower-test-growth-to-get-paid-some-orders-cannot-be-reimbursed-2507987b/)
- [GeneDx Lowers Core Testing Growth Target To At Least 17% — But Keeps Sales Forecast](https://www.bullished.co/genedx-lowers-core-testing-growth-target-to-at-least-17-but-keeps-sales-forecast-3dc61c74/)

[All GeneDx (WGS) coverage →](https://www.bullished.co/tag/wgs/)